Exelixis (EXEL)
(Delayed Data from NSDQ)
$37.26 USD
+1.04 (2.87%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $37.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXEL 37.26 +1.04(2.87%)
Will EXEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Other News for EXEL
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Exelixis (EXEL) Neutral Rating Maintained by UBS, Price Target Lowered | EXEL Stock News
Exelixis (EXEL) Target Price Reduced by UBS to $38
Exelixis price target lowered by $5 at UBS